Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF plus lomustine in recurrent glioblastoma at first progression
2022-501822-39-00Phase 2Completed
- Sponsor
- Philogen
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2 trial of onfekafusp alfa and lomustine in glioblastoma (GBM), sponsored by Philogen. Started Jul 2023; status: completed.
02
Drugs
onfekafusp alfalomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2022-501822-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501822-39-00.